A bill to amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.

Amends the Federal Food, Drug, and Cosmetic Act to prohibit a holder of a new, approved drug application from manufacturing, marketing, selling, or distributing a generic version of such drug during any exclusivity period granted to manufacturers of generic brands.